Literature DB >> 17200799

Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE).

Farzana Kapadia1, Mary H Latka, Holly Hagan, Elizabeth T Golub, Jennifer V Campbell, Micaela H Coady, Richard S Garfein, David L Thomas, Sebastian Bonner, Thelma Thiel, Steffanie A Strathdee.   

Abstract

Hepatitis C virus (HCV) is hyperendemic among injection drug users (IDUs). However, few scientifically proven interventions to prevent secondary transmission of HCV from infected IDUs to others exist. This report describes the design, feasibility, and baseline characteristics of participants enrolled in the Study to Reduce Intravenous Exposure (STRIVE). STRIVE was a multisite, randomized-control trial to test a behavioral intervention developed to reduce distribution of used injection equipment (needles, cookers, cottons, and rinse water) and increase health-care utilization among antibody HCV (anti-HCV) positive IDUs. STRIVE enrolled anti-HCV positive IDU in Baltimore, New York City, and Seattle; participants completed behavioral assessments and venipuncture for HIV, HCV-RNA, and liver function tests (LFTs) and were randomized to attend either a six-session, small-group, peer-mentoring intervention workshop or a time-matched, attention-control condition. Follow-up visits were conducted at 3 and 6 months. At baseline, of the 630 HCV-positive IDUs enrolled (mean age of 26 years, 60% white, 76% male), 55% reported distributive needle sharing, whereas 74, 69, and 69% reported sharing cookers, cottons, and rinse water, respectively. Health-care access was low, with 41% reporting an emergency room as their main source of medical care. Among those enrolled, 66% (418/630) were randomized: 53% (222/418) and 47% (196/418) to the intervention and control conditions, respectively. Follow-up rates were 70 and 73% for the 3- and 6-month visits, respectively. As distributive sharing of used injection equipment was common while reports of receiving HCV care were low, these findings indicate an urgent need for HCV-related interventions with IDUs and demonstrate the acceptability and feasibility to do so.

Entities:  

Mesh:

Year:  2007        PMID: 17200799      PMCID: PMC2078252          DOI: 10.1007/s11524-006-9133-7

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  32 in total

1.  Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial.

Authors:  D C Des Jarlais; D Paone; J Milliken; C F Turner; H Miller; J Gribble; Q Shi; H Hagan; S R Friedman
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

Review 3.  The epidemiology of hepatitis C virus infection.

Authors:  Tommy Yen; Emmet B Keeffe; Aijaz Ahmed
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

4.  Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology.

Authors:  C F Turner; L Ku; S M Rogers; L D Lindberg; J H Pleck; F L Sonenstein
Journal:  Science       Date:  1998-05-08       Impact factor: 47.728

5.  Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team.

Authors:  D S Metzger; B Koblin; C Turner; H Navaline; F Valenti; S Holte; M Gross; A Sheon; H Miller; P Cooley; G R Seage
Journal:  Am J Epidemiol       Date:  2000-07-15       Impact factor: 4.897

6.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

7.  The impact of injecting drug use status on hepatitis C-related referral and treatment.

Authors:  M A Stoové; S M Gifford; G J Dore
Journal:  Drug Alcohol Depend       Date:  2005-01-07       Impact factor: 4.492

8.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

9.  Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

Authors:  Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 10.  NIH Consensus Statement on Management of Hepatitis C: 2002.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jun 10-12
View more
  15 in total

1.  Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.

Authors:  Michael C Clatts; Vivian Colón-López; Le M Giang; Lloyd A Goldsamt
Journal:  J Urban Health       Date:  2010-03       Impact factor: 3.671

2.  Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.

Authors:  Judith A Hahn; Dennis Wylie; Jesse Dill; Maria S Sanchez; James O Lloyd-Smith; Kimberly Page-Shafer; Wayne M Getz
Journal:  Epidemics       Date:  2009-03       Impact factor: 4.396

3.  Intimate Strangers? Social Networks in HIV Prevention Groups for Drug Users.

Authors:  Thomas Lyons; Krystal Madkins; Pritesh Karia; Grady Garner
Journal:  J Groups Addict Recover       Date:  2013-04-01

4.  Individual and socio-environmental factors associated with unsafe injection practices among young adult injection drug users in San Diego.

Authors:  Fátima Muñoz; José Luis Burgos; Jazmine Cuevas-Mota; Eyasu Teshale; Richard S Garfein
Journal:  AIDS Behav       Date:  2015-01

5.  Health consequences of long-term injection heroin use among aging Mexican American men.

Authors:  Luis R Torres; Charles Kaplan; Avelardo Valdez
Journal:  J Aging Health       Date:  2011-03-30

6.  Traveling young injection drug users at high risk for acquisition and transmission of viral infections.

Authors:  Judith A Hahn; Kimberly Page-Shafer; Jamye Ford; Alan Paciorek; Paula J Lum
Journal:  Drug Alcohol Depend       Date:  2007-11-05       Impact factor: 4.492

7.  A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.

Authors:  Mary H Latka; Holly Hagan; Farzana Kapadia; Elizabeth T Golub; Sebastian Bonner; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; Minya Pu; Dave L Thomas; Thelma K Thiel; Steffanie A Strathdee
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

8.  The association of syringe type and syringe cleaning with HCV infection among IDUs in Budapest, Hungary.

Authors:  V Anna Gyarmathy; Alan Neaigus; Mary M Mitchell; Eszter Ujhelyi
Journal:  Drug Alcohol Depend       Date:  2008-12-05       Impact factor: 4.492

9.  Giving away used injection equipment: missed prevention message?

Authors:  Carol Strike; Daniel Z Buchman; Russell C Callaghan; Cass Wender; Susan Anstice; Brian Lester; Nick Scrivo; Janine Luce; Margaret Millson
Journal:  Harm Reduct J       Date:  2010-02-09

10.  Awareness of hepatitis C infection among women with and at risk for HIV.

Authors:  Mardge H Cohen; Dennis Grey; Judith A Cook; Kathryn Anastos; Eric Seaberg; Michael Augenbraun; Pam Burian; Marion Peters; Mary Young; Audrey French
Journal:  J Gen Intern Med       Date:  2007-10-09       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.